Accuray Unveils Groundbreaking Research on 5 Session Radiotherapy for Prostate Cancer at ESTRO 2025

Accuray Presents New Long-Term Study on CyberKnife® for Prostate Cancer at ESTRO 2025

Accuray Incorporated has made a significant impact at the European Society for Radiotherapy and Oncology (ESTRO) 2025 meeting held in Vienna, Austria, by unveiling new data that emphasizes the effectiveness of the company's CyberKnife® System in treating prostate cancer. With multiple clinical studies presented, the focus was on how this cutting-edge technology enhances patient care through precision and reduced treatment times.

The data reinforces the advantages of stereotactic body radiation therapy (SBRT) provided by the CyberKnife System, particularly for men facing various stages of prostate cancer, including those with high-risk disease and cases of cancer recurrence after prostatectomy. Suzanne Winter, president and CEO of Accuray, highlighted the importance of the findings, stating, "Our studies reveal not only the efficacy of our technology but also its adaptability as a primary treatment option alongside other modalities like chemotherapy or surgery. Many patients benefit tremendously from our long-term follow-ups, displaying positive quality of life indicators up to a decade after treatment."

During the congress, Accuray conducted a symposium that attracted over 350 healthcare professionals. This event served as a forum for discussing the latest advancements in genitourinary radiotherapy, particularly focusing on prostate, kidney, and bladder cancers. The discussions underscored a pivotal shift within the medical community, advocating for SBRT as a validated alternative to standard treatments for localized prostate cancer, with continuous evidence emerging for its role in salvage therapies.

Notable Studies Presented

Among the notable studies was a retrospective analysis involving 262 men over the age of 70, or with significant comorbidities, diagnosed with high-risk prostate cancer. This group underwent SBRT using the CyberKnife System across five treatment sessions. The results, gathered over a median follow-up period of 39 months, indicated not only promising clinical outcomes but also low rates of acute and late genitourinary and gastrointestinal toxicities.

Another key study, "Early results from a trial on stereotactic salvage radiotherapy for macroscopic prostate bed recurrence after prostatectomy STARR (NCT05455736)," explored the potential of SSRT delivered with the CyberKnife. In this prospective assessment involving 51 patients, early results revealed that the CyberKnife System not only provides a highly effective treatment approach but does so with minimal toxicity. The researchers praised the shorter treatment durations as a significant advantage, making it a preferred option for patients reeling from cancer recurrence.

Accuray's commitment to innovation is evident through these studies, showcasing their dedication to advancing patient care in oncology. The company aims to continue expanding radiation therapy's potential, ensuring that patients experiencing complex health challenges have access to effective treatment options.

Beyond the conference highlights, the commitment to patient-centered care remains at the forefront of Accuray’s mission. With technological advancements and a focus on personalized medicine, Accuray continues to set the stage for transformative changes in how prostate cancer and other complex conditions are treated.

For more about Accuray and their innovative treatments, you can visit their official website. They maintain a robust presence on social media platforms like Facebook and LinkedIn, where they share the latest updates and insights related to their technologies and ongoing research endeavors.

Conclusion

Accuray’s presentations at ESTRO 2025 not only underline the effectiveness of the CyberKnife system in treating prostate cancer but also reshape existing paradigms regarding radiotherapy. As more healthcare professionals adopt SBRT techniques, the hope is that patient outcomes will significantly improve, further enhancing the quality of life and care for those battling prostate cancer.